Acute Rheumatic Fever Treatment & Management
- Author: Robert J Meador, Jr, MD; Chief Editor: Herbert S Diamond, MD more...
Treatment strategies for acute rheumatic fever (ARF) can be divided into management of the acute attack, management of the current infection, and prevention of further infection and attacks.
The primary goal of treating an ARF attack is to eradicate streptococcal organisms and bacterial antigens from the pharyngeal region. Penicillin is the drug of choice in persons who are not at risk of allergic reaction. A single parenteral injection of benzathine benzylpenicillin can ensure compliance. Oral cephalosporins, rather than erythromycin, are recommended as an alternative in patients who are allergic to penicillin. However, be cautious of the 20% cross-reactivity of the cephalosporins with penicillin.
Prompt treatment of streptococcal pharyngitis in susceptible hosts can prevent repetitive exposure to pathologically reactive antigens.[12, 13] However, management of the current infection will probably not affect the course of the current attack. Antimicrobial therapy does not alter the course, frequency, or severity of cardiac involvement.
Analgesia is optimally achieved with high doses of salicylates, which often induce dramatic clinical improvement. However, a lower dose may be required to avert symptoms of nausea and vomiting. When salicylates are used as therapy, the dosage should be increased until the drug produces either a clinical effect or systemic toxicity characterized by tinnitus, headache, or hyperpnea.
Corticosteroids should be reserved for the treatment of severe carditis. After 2-3 weeks, the dosage may be tapered, reduced by 25% each week. Overlap with high-dose salicylate therapy is recommended as the dosage of the prednisone is tapered over a 2-week period to avoid poststeroid rebound. In extreme cases, intravenous methylprednisolone may be used.
Mild heart failure usually responds to rest and corticosteroid therapy. Digoxin can be useful in patients with severe carditis, but its use should be monitored closely because of the possibility of heart block.
Nocturnal tachycardia may be a sign of cardiac involvement that may be responsive to digoxin. Vasodilators and diuretics also may be used.
Protracted Sydenham chorea has responded to haloperidol. Chorea requires long-term antimicrobial prophylaxis, even if no other manifestations of rheumatic fever evolve. The signs and symptoms of chorea usually do not respond well to treatment with antirheumatic agents. Complete physical and mental rest is essential because the manifestations of chorea may be exaggerated by emotional trauma. Glucocorticoids or salicylates have little or no effect on chorea. Because chorea disappears with sleep, adequate sedation should be provided.
Prevention has been successful in developed societies. The recommended approach can be divided into primary and secondary prevention. Primary prevention involves eradication of Streptococcus from the pharynx, which generally entails administering a single intramuscular injection of benzathine benzylpenicillin.
The American Heart Association (AHA) Committee on Acute Rheumatic Fever recommends a regimen consisting of benzathine benzylpenicillin at 1.2 million units intramuscularly every 4 weeks. However, in high-risk situations, administration every 3 weeks is justified and advised. High-risk situations include patients with heart disease who are at risk of repetitive exposure.
Oral prophylaxis, which is less reliable, consists of phenoxymethylpenicillin (penicillin V) or sulfadiazine. These can be used in compliant patients.
If penicillin allergy is suspected, oral cephalosporins should be used.
Although no consensus on the required duration of antibacterial prophylaxis has been reached, the AHA recommends that prophylaxis be continued for at least 10 years after the last episode of rheumatic fever or until patients are well into adulthood. For those with heart disease who are at risk of repetitive exposures, prophylaxis should be continued for a longer duration, probably indefinitely. However, discontinuing prophylaxis may be reasonable in patients in their third decade of life in whom more than 5 years have passed since their last attack and who are free from rheumatic heart disease.
The principles of treatment include the following:
The risk of rheumatic fever recurrence is greatest during the first 3-5 years following the attack.
Prophylaxis must continue indefinitely in patients with established heart disease or in those frequently exposed to streptococci.
Treatment for an indefinite period is required among patients with frequent exposure to streptococci or for those who are difficult to monitor.
In underdeveloped countries, prophylaxis should be continued as follows:
Continue for 5 years after the first attack
Continue indefinitely in patients with established heart disease
Continue indefinitely in patients who are frequently exposed to streptococci and are difficult to monitor
The decision to withdraw antibacterial treatment should be individualized after carefully assessing the risk of repetitive exposures.
Valve replacement should be considered in patients with active carditis, especially those with cases that are refractory to medical care or require high doses of vasodilators and diuretics.
Regurgitant lesions respond to valve replacement. Pure stenotic lesions may benefit from more conservative balloon mitral commissurotomy.
Primary care physicians should be considered the patient's advocate and guide to medical resources. The role of specialists is as follows:
Rheumatologists usually assist in diagnosis in the face of a substantial differential; when the diagnosis is established, they can advise on the therapy plan
A cardiologist should be consulted when cardiac involvement is present
A neurologist may offer interventions to help manage chorea
See the list below:
All patients should be restricted to bed rest and monitored closely for carditis.
Aggressive use of acutely inflamed joints or other exercise may cause permanent joint injury to acutely inflamed joints.
When carditis has been documented, a 4-week period of bed rest is recommended. As soon as the signs of acute inflammation subside, patients should resume active ambulation as tolerated.
Most patients can be treated safely in an outpatient setting.
Dale RC. Immune-mediated extrapyramidal movement disorders, including Sydenham chorea. Handb Clin Neurol. 2013. 112:1235-41. [Medline].
Yoshinoya S, Pope RM. Detection of immune complexes in acute rheumatic fever and their relationship to HLA-B5. J Clin Invest. 1980 Jan. 65(1):136-45. [Medline].
Bryant PA, Smyth GK, Gooding T, Oshlack A, Harrington Z, Currie B, et al. Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. Infect Immun. 2014 Feb. 82(2):753-61. [Medline]. [Full Text].
Erdem G, Mizumoto C, Esaki D, Reddy V, Kurahara D, Yamaga K, et al. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis. 2007 Aug 1. 45(3):e20-4. [Medline].
Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart. 2008 Dec. 94(12):1534-40. [Medline].
Pennock V, Bell A, Moxon TA, Reed P, Maxwell F, Lennon D. Retrospective epidemiology of acute rheumatic fever: a 10-year review in the Waikato District Health Board area of New Zealand. N Z Med J. 2014 May 2. 127(1393):26-37. [Medline].
[Guideline] Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov 15. 55(10):e86-102. [Medline].
NINDS Sydenham Chorea Information Page. National Institute of Neurological Disorders and Stroke. Available at http://www.ninds.nih.gov/disorders/sydenham/sydenham.htm. Accessed: December 10, 2104.
Barash J, Mashiach E, Navon-Elkan P, Berkun Y, Harel L, Tauber T, et al. Differentiation of post-streptococcal reactive arthritis from acute rheumatic fever. J Pediatr. 2008 Nov. 153(5):696-9. [Medline].
Jones TD. Diagnosis of rheumatic fever. JAMA. 1944. 126:481-85.
[Guideline] Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015 May 19. 131 (20):1806-18. [Medline]. [Full Text].
Irlam JH, Mayosi BM, Engel ME, Gaziano TA. A cost-effective strategy for primary prevention of acute rheumatic fever and rheumatic heart disease in children with pharyngitis. S Afr Med J. 2013 Sep 3. 103(12):894-5. [Medline].
Fine AM, Nizet V, Mandl KD. Participatory medicine: a home score for streptococcal pharyngitis enabled by real-time biosurveillance: a cohort study. Ann Intern Med. 2013 Nov 5. 159(9):577-83. [Medline].
Lennon D, Stewart J, Anderson P. Primary Prevention of Rheumatic Fever. Pediatr Infect Dis J. 2016 Jul. 35 (7):820. [Medline].
[Guideline] Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009 Mar 24. 119(11):1541-51. [Medline].
He VY, Condon JR, Ralph AP, Zhao Y, Roberts K, de Dassel JL, et al. Long Term Outcomes from Acute Rheumatic Fever and Rheumatic Heart Disease: A Data-Linkage and Survival Analysis Approach. Circulation. 2016 Jul 12. [Medline].
Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation. 2009 Feb 10. 119(5):742-53. [Medline].
Carapetis JR, Brown A, Wilson NJ, Edwards KN, Rheumatic Fever Guidelines Writing Group. An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. Med J Aust. 2007 Jun 4. 186(11):581-6. [Medline].
Erdem G, Mizumoto C, Esaki D, Reddy V, Kurahara D, Yamaga K. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis. 2007 Aug 1. 45(3):e20-4. [Medline].
Gibofsky A, Kerwar S, Zabriskie JB. Rheumatic fever. The relationships between host, microbe, and genetics. Rheum Dis Clin North Am. 1998 May. 24(2):237-59. [Medline].
Guzman, L. Rheumatic Fever. Klippel J, ed. Primer on the Rheumatic Diseases. 11th ed. Atlanta, Ga: Arthritis Foundation; 1997. 168-71.
Gündogdu F, Islamoglu Y, Pirim I, Gurlertop Y, Dogan H, Arslan S. Human leukocyte antigen (HLA) class I and II alleles in Turkish patients with rheumatic heart disease. J Heart Valve Dis. 2007 May. 16(3):293-9. [Medline].
Kaplan EL. Pathogenesis of acute rheumatic fever and rheumatic heart disease: evasive after half a century of clinical, epidemiological, and laboratory investigation. Heart. 2005 Jan. 91(1):3-4. [Medline].
McLean A, Waters M, Spencer E, Hadfield C. Experience with cardiac valve operations in Cape York Peninsula and the Torres Strait Islands, Australia. Med J Aust. 2007 Jun 4. 186(11):560-3. [Medline].
Minola E, Arosio M, Rizzo G, et al. Clinical and laboratory features of acute rheumatic fever: a 18-year experience. Infez Med. 2005. 13(1):28-32. [Medline].
Soudarssanane MB, Karthigeyan M, Mahalakshmy T, Sahai A, Srinivasan S, Subba Rao KS. Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective option. Indian J Pediatr. 2007 Jun. 74(6):567-70. [Medline].
Stanevicha V, Eglite J, Zavadska D, Sochnevs A, Shantere R, Gardovska D. HLA Class II DR and DQ genotypes and haplotypes associated with rheumatic fever among clinically homogenous patients in children in Latvia. Arthritis Res Ther. 2007 Jun 10. 9(3):R58. [Medline].
Weidebach W, Goldberg AC, Chiarella JM, et al. HLA class II antigens in rheumatic fever. Analysis of the DR locus by restriction fragment-length polymorphism and oligotyping. Hum Immunol. 1994 Aug. 40(4):253-8. [Medline].
Zakkar M, Amirak E, Chan KM, Punjabi PP. Rheumatic mitral valve disease: current surgical status. Prog Cardiovasc Dis. 2009 May-Jun. 51(6):478-81. [Medline].